Tetra Bio Pharma Inc TBPMQ

Healthcare Cannabis

Tetra Bio-Pharma Inc. is a Canada-based cannabinoid-derived drug discovery and development company. The Company has developed a pipeline of cannabinoid-based drug products for a range of medical conditions, including pain, inflammation, and oncology. The Company has a pipeline of formulations and drug delivery systems with a portfolio of assets from the early research and development phase to advanced stage clinical programs. Its products include QIXLEEF, CAUMZ, PPP004, REDUVO, and REBORN 1. QIXLEEF is a botanical therapy with a fixed dosage of tetrahydrocannabinol (THC) and cannabidiol (CBD). CAUMZ is its inhaled cannabinoid-derived drug candidate. PPP004 is a topical preparation containing either a standardized amount of CBD or a defined ratio of THC and CBD. REDUVO is a soft gel capsule used to treat chemotherapy-induced nausea and vomiting (CINV) and weight loss and severe nausea in people living with human immunodeficiency virus (HIV) infection. REBORN 1 is in phase II trial.

GREY:TBPMQ - Post by User

Tetra Bio Pharma Inc > TBP PROVIDES MANAGEMENT UPDATE (long detailed)

<< Previous

Bullboard Posts

Next >>

Comment by Golddetectoron Feb 28, 2022 8:54pm

158 Views

Post# 34469636

RE:TBP PROVIDES MANAGEMENT UPDATE (long detailed)

It is kind of status update. Nothing new Other than reductions in burn rate to 1.2M. 4.8M in the bank as of Nov 30. Add 2.1M from recent pp so 6.9M in the bank - 3x1.2 = 3.3M in the bank as of end of Feb. so we can go another 3 months with loans or pps. Many ppl thought they are out of money already. It looks like Reborn showing positive results and they want to expand beyond cancer but the trial is taking so long. Reduvo seems to be close nothing pending just official communication.

<< Previous

Bullboard Posts

Next >>

Silvercorp to expand into Ecuador with C$200M Adventus acquisition